Evidence map›Paper›PMID 40488799›Full record

ArticleClinical and experimental medicine2025

Elevated eosinophil-to-lymphocyte ratio (ELR) as a predictor of relapse for IgG4-related disease: a retrospective study across a decade.

Nianyi Zhang, Yu Peng, Rongli Li, Yuxue Nie, Jingna Li, Xinli Yang, Jialei Zhang, Yifei Wang, Qinhuan Luo, Jiaxin Zhou and 4 more

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nianyi Zhang *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Yu Peng *Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang, Hangzhou, China.
Rongli Li *Department of Rheumatology and Immunology, The First People's Hospital of Yunnan Province, the affiliated hospital of Kunming University of Science and Technology, Yunnan, Kunming, China.
Yuxue NieDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Jingna LiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Xinli YangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Jialei ZhangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Yifei WangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Qinhuan LuoDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Jiaxin ZhouDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Yunyun FeiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Mengtao LiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Linyi PengDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China. drpenglinyi@163.com.
Wen ZhangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China. zhangwen91@sina.com.

Funding

Beijing Natural Science Foundation 7232113CAMS Innovation Fund for Medical Sciences CIFMS 2021-1-I2M-003, 2022-I2M-C&T-B-005National High Level Hospital Clinical Research Funding (2022-PUMCH-C-006,2022-PUMCH-A-041,2022-PUMCH-B-013National Key Research and Development Program of China 2022YFC2703104National Natural Science Foundation of China 82271848, 823B2037, 82471829
6 · The paper itself

Abstract

To investigate the clinical significance of leukocyte-to-lymphocyte ratios, particularly the eosinophil-to-lymphocyte ratio (ELR) and basophil-to-lymphocyte ratio (BLR), in IgG4-related disease (IgG4-RD). We enrolled 541 treatment-naïve IgG4-RD patients and compared their ELR, BLR, neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR) with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and primary Sjögren's syndrome (pSS) patients. K-means cluster analysis was performed to categorize enrolled IgG4-RD patients based on inflammatory markers (ELR, BLR, NLR, Complement 3, Complement 4, erythrocyte sedimentation rate), and clinical data of different clusters were analyzed using statistical methods including Kaplan-Meier curves and Cox regression. ELR and BLR levels were significantly elevated in IgG4-RD patients (ELR: 0.11 [0.05-0.22]; BLR: 0.02 [0.01-0.03]) compared to SLE, RA, and pSS patients (all P < 0.001). ELR was strongly associated with higher disease activity, increased serum IgG4, the number of affected organs, and proliferative phenotype proportions in IgG4-RD patients. We identified a high-risk subgroup of IgG4-RD patients with high ELR/BLR and low complement 3/4 (C3/C4) through clustering analysis. This subgroup exhibited higher disease activity and relapse risk. And IgG4-RD patients with high ELR (≥ 0.1103) had higher relapse rates during follow-up (HR = 2.12, 95% CI 1.37-3.26, P = 0.0005). ELR was identified as a risk factor for relapse in IgG4-RD patients. Our study indicated that the significantly elevated ELR reflects Th2 immune dysregulation and disease severity in IgG4-RD and serves as an independent predictor of relapse, offering a potential biomarker for personalized management.

Indexed as

EosinophilsImmunoglobulin G4-Related DiseaseLymphocytesAdultAgedBiomarkersFemaleHumansImmunoglobulin GLeukocyte CountMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesBiomarkersImmunoglobulin GBasophil-to-lymphocyte ratioEosinophil-to-lymphocyte ratioIgG4-related diseaseRelapse

Identifiers

PMID40488799
PMCPMC12148991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.